

MARKET REPORT



Ulcerative Colitis: Epidemiology Forecast to 2026

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ulcerative Colitis: Epidemiology Forecast to 2026

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ulcerative Colitis: Epidemiology Forecast to 2026

Ulcerative Colitis: Epidemiology Forecast to 2026

Summary

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining of the colon. UC commonly affects teenagers and young adults, and can result in poor development and growth; however, the disease can also occur in children and older individuals. Unlike Crohn's disease (CD), another form of IBD that has similar symptoms to UC but can occur anywhere in the digestive tract and features ulceration deep into the tissues, UC is limited to the colon and has less frequent complications.

GlobalData's epidemiological forecast for the diagnosed incidence, diagnosed prevalence, undiagnosed prevalence, and total prevalence of UC in the 7MM is supported by nationally representative, country-specific studies published in peer-reviewed journals of national healthcare databases and registries. In addition, to improve the comparability of the forecast diagnosed incident and diagnosed prevalent cases of UC across markets, GlobalData epidemiologists used sources that provided uniform diagnostic criteria for these subcategories.

In the 7MM, the diagnosed incident cases of UC are expected to increase from 94,303 cases in 2016 to 108,428 cases in 2026, at an Annual Growth Rate (AGR) of 1.5%. The US will have the highest number of diagnosed incident cases of UC over the forecast period, while Spain will have the lowest. In the 7MM, the diagnosed prevalent cases of UC are expected to increase from 1,737,130 cases in 2016 to 1,867,305 cases in 2026, at an AGR of 0.75%. The US will have the highest number of diagnosed prevalent cases of UC over the forecast period, while Spain will have the lowest.

Scope

- The Ulcerative Colitis (UC) Epidemiology Forecast Report provides an overview of the risk factors and global trends of UC in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, undiagnosed prevalent cases, and total prevalent cases (both diagnosed and undiagnosed) of UC, segmented by sex and age (starting at ages 0-9 years and ending at ages 80 years and older) in these markets. The diagnosed incident cases are further segmented by stage at diagnosis and severity grading. The diagnosed prevalent cases are further segmented by severity grading. Additionally, autoimmune comorbidities, colectomy due to failure of medical management, and mortality due to complications of UC among the diagnosed prevalent cases of UC are also included in this analysis. Furthermore, the report includes diagnosed incident cases and diagnosed prevalent cases of indeterminate colitis (IC) for both sexes and all ages in the 7MM.
- The Ulcerative Colitis epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Ulcerative Colitis (UC) Epidemiology Forecast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global UC market.
- Quantify patient populations in the global UC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for UC therapeutics in each of the markets covered.
- Understand magnitude of UC population by severity, stage at diagnosis, comorbidities, and other clinically relevant segmentations.

Additional Details

Publisher : Global Data

Reference : GDHCER189-18

Number of Pages : 64

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Ulcerative Colitis: Epidemiology Forecast to 2026

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 42 Ulcerative Colitis: Executive Summary 52.1 Related Reports 72.2 Upcoming Reports 73 Epidemiology 83.1 Disease Background 83.2 Risk Factors and Comorbidities 93.3 Global and Historical Trends 93.4 Forecast Methodology 113.4.1 Sources 123.4.2 Forecast Assumptions and Methods 223.5 Epidemiological Forecast for UC (2016-2026) 363.5.1 Diagnosed Incident Cases of UC 363.5.2 Age-Specific Incident Cases of UC 373.5.3 Sex-Specific Incident Cases of UC 383.5.4 Diagnosed Incident Cases of UC by Stage at Diagnosis 393.5.5 Diagnosed Incident Cases of UC by Severity 403.5.6 Diagnosed Prevalent Cases of UC 413.5.7 Age-Specific Diagnosed Prevalent Cases of UC 423.5.8 Sex-Specific Diagnosed Prevalent Cases of UC 433.5.9 Diagnosed Prevalent Cases of UC by Severity 443.5.10 Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC 453.5.11 Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC 463.5.12 Comorbidities of UC Among the Diagnosed Prevalent Cases of UC 473.5.13 Undiagnosed Prevalent Cases of UC 483.5.14 Total Prevalent Cases of UC 493.5.15 Diagnosed Incident Cases of IC 503.5.16 Diagnosed Prevalent Cases of IC 513.6 Discussion 523.6.1 Epidemiological Forecast Insight 523.6.2 Limitations of Analysis 523.6.3 Strengths of Analysis 534 Appendix 554.1 Bibliography 554.2 Primary Research - KOLs Interviewed for this Report 604.3 About the Authors 614.3.1 Epidemiologist 614.3.2 Reviewers 614.3.3 Global Director of Therapy Analysis and Epidemiology 624.3.4 Global Head and EVP of Healthcare Operations and Strategy 624.4 About GlobalData 634.5 Contact Us 634.6 Disclaimer 63

List Of Tables in Ulcerative Colitis: Epidemiology Forecast to 2026

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for UC and IBD 9

List Of Figures, Charts and Diagrams in Ulcerative Colitis: Epidemiology Forecast to 2026

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, 2016 and 2026 6

Figure 2: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016 and 2026 7

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2016 10

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of UC (%), All Ages, Both Sexes, N, 2016 11

Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of UC 12

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of UC 13

Figure 7: 7MM, Sources Used, Undiagnosed Prevalent Cases of UC 14

Figure 8: 7MM, Sources Used, Total Prevalent Cases of UC 15

Figure 9: 7MM, Sources Used, Diagnosed Incident Cases of UC by Stage at Diagnosis 16

Figure 10: 7MM, Sources Used, Diagnosed Incident Cases of UC by Severity 17

Figure 11: 7MM, Sources Used, Diagnosed Prevalent Cases of UC by Severity 18

Figure 12: 7MM, Sources Used, Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC 18

Figure 13: 7MM, Sources Used, UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management 19

Figure 14: 7MM, Sources Used, Diagnosed Incident Cases of IC 20

Figure 15: 7MM, Sources Used, Diagnosed Prevalent Cases of IC 21

Figure 16: Diagnosed Incident Cases of UC, 7MM, Men and Women, All Ages, 2016 36

Figure 17: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N, 2016 37

Figure 18: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2016 38

Figure 19: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2016 39

Figure 20: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2016 40

Figure 21: Diagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016 41

Figure 22: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2016 42

Figure 23: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2016 43

Figure 24: 7MM, Diagnosed Prevalent Cases of UC by Severity, Both Sexes, ≥ 18 Years, N, 2016 44

Figure 25: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016 45

Figure 26: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016 46

Figure 27: 7MM, Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016 47

Figure 28: Undiagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016 48

Figure 29: Total Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016 49

Figure 30: Diagnosed Incident Cases of IC, 7MM, Men and Women, All Ages, 2016 50

Figure 31: Diagnosed Prevalent Cases of IC, 7MM, Men and Women, All Ages, 2016 51

How to Buy...

Ulcerative Colitis: Epidemiology Forecast to 2026

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/215615>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3396** | Single User Price
- \$6792** | Site License Price
- \$10187** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.